首页> 外文OA文献 >Efficacy and safety of two doses of S 90098 (1 and 2 mg/day), sublingual formulation for 8 weeks in out-patients with major depressive disorder: An 8-week randomised, double-blind, fixed dose, international, multicentre, placebo-controlled study with parallel groups, followed by an extension double-blind treatment period for 16 weeks

【2h】

Efficacy and safety of two doses of S 90098 (1 and 2 mg/day), sublingual formulation for 8 weeks in out-patients with major depressive disorder: An 8-week randomised, double-blind, fixed dose, international, multicentre, placebo-controlled study with parallel groups, followed by an extension double-blind treatment period for 16 weeks

机译：两剂S 90098（1和2毫克/天）的疗效和安全性，舌下制剂8周，患有主要抑郁症的患者：8周随机化，双盲，固定剂量，国际，多期，安慰剂 - 与平行组进行控制，然后进行延伸双盲治疗期16周

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Frédéric Rouillon;
展开▼
作者单位

展开▼
年度 2012
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献

1. Long-Term (1 Year) Safety and Efficacy of Methylphenidate Modified-Release Long-Acting Formulation (MPH-LA) in Adults with Attention-Deficit Hyperactivity Disorder: A 26-Week, Flexible-Dose, Open-Label Extension to a 40-Week, Double-Blind, Randomised, Placebo-Controlled Core Study [J] . Ginsberg Y., Arngrim T., Philipsen A., CNS drugs . 2014,第10期

机译：患有注意力缺陷多动障碍的成年人的哌醋甲酯修饰释放长效制剂（MPH-LA）的长期（1年）安全性和有效性：26周，灵活剂量，开放标签扩展至40-周，双盲，随机，安慰剂对照核心研究
2. A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder [J] . HenigsbergN., MahableshwarkarA.R., JacobsenP., The journal of clinical psychiatry . 2012,第7期

机译：一项双盲，安慰剂对照，为期8周的随机试验，涉及多剂Lu AA21004在重症抑郁症患者中的疗效和耐受性
3. Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial. [J] . Feiger AD, Rickels K, Rynn MA, The journal of clinical psychiatry . 2006,第9期

机译：司来吉兰透皮系统治疗重度抑郁症的研究：一项为期8周，双盲，安慰剂对照，剂量可调的滴定试验。
4. Long-Term (1 Year) Safety and Efficacy of Methylphenidate Modified-Release Long-Acting Formulation (MPH-LA) in Adults with Attention-Deficit Hyperactivity Disorder: A 26-Week Flexible-Dose Open-Label Extension to a 40-Week Double-Blind Randomised Placebo-Controlled Core Study [O] . Y. Ginsberg, T. Arngrim, A. Philipsen, -1

机译：患有注意力缺陷多动障碍的成年人的哌醋甲酯修饰释放长效制剂（MPH-LA）的长期（1年）安全性和有效性：26周灵活剂量开放标签扩展到40-周双盲随机安慰剂对照核心研究
5. Long-term efficacy and safety of agomelatine in non-depressed out-patients with generalized anxiety disorder. A 26-week randomised double-blind placebo-controlled parallel group study following an open-label period of 16 weeks with agomelatine (25 mg/day with the possibility for blinded dose-adjustment to 50 mg/day) [O] . Istvan Bitter 2012

机译：广义焦虑症非抑郁患者的长期疗效和治疗症的安全性。一个26周的随机双盲安慰剂控制并行组在含有胍盐碱的开放标签期间（25毫克/天，致盲剂量调节至50毫克/天）

著录项

引文网络

相似文献

相关主题

期刊订阅